Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors

Дата публикации: 27-08-2026 00:00:00

Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL	0	2.16	27-08-2026
2	ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY	0	2.3	27-08-2026
3	NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	0	5	27-08-2026
4	Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL	0	14.76	06-08-2026
5	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
6	Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma	0	5	02-07-2026
7	RANDOMIZED COMPARISON OF IBRUTINIB <i>VERSUS</i> OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL	0	2.29	27-08-2026
8	Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature review	0	13.23	20-08-2026
9	Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	0	14.62	23-07-2026
10	EMA Recommends Extension of Therapeutic Indications for Epcoritamab	0	8.04	24-07-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5.21. Источник: escholarship.org.